Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

58.44
+0.11000.19%
Post-market: 58.16-0.2800-0.48%17:10 EDT
Volume:2.37M
Turnover:139.25M
Market Cap:14.48B
PE:18.38
High:59.27
Open:58.47
Low:57.88
Close:58.33
52wk High:61.14
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:1.08
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.85
PE(LYR):21.02

Loading ...

Exelixis price target raised to $54 from $52 at Truist

TIPRANKS
·
Yesterday

US Research Roundup-Allstate, Caribou Biosciences, Zscaler

Reuters
·
Yesterday

Exelixis Inc : Jefferies Raises Target Price to $70 from $66

THOMSON REUTERS
·
Yesterday

Exelixis Inc : Leerink Partners Assumes Coverage with Market Perform Rating; Target Price $55

THOMSON REUTERS
·
Oct 05

EXEL Industries Updates Share Capital and Voting Rights as of September 30, 2026

TIPRANKS
·
Oct 03

Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)

TIPRANKS
·
Sep 14

Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed

TIPRANKS
·
Sep 14

FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating

TIPRANKS
·
Sep 13

Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)

TIPRANKS
·
Sep 13

Sector Update: Healthcare Stocks Ease in Afternoon Trading

MT Newswires Live
·
Sep 12

Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair

TIPRANKS
·
Sep 12

Analysts Offer Insights on NA Companies: Exelixis (EXEL) and HEICO (HEI)

TIPRANKS
·
Sep 11

Exelixis Shares Fall 3% After US FDA Extends Review of Co's Cancer Drug

THOMSON REUTERS
·
Sep 11

U.S. FDA Extends Review of Exelixis' Cancer Drug

Reuters
·
Sep 11

Exelixis - FDA Extends Review Period for Exelixis Nda for Zanzalintinib and Atezolizumab by Three Months - SEC Filing

THOMSON REUTERS
·
Sep 11

Adagene Receives Milestone Payment From Exelixis

MT Newswires Live
·
Sep 09

Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration

TIPRANKS
·
Sep 09

Adagene Receives USD 2 Million Exelixis Milestone Payment for SAFEbody ADC Program

Reuters
·
Sep 09

Adagene Hits Preclinical Milestone for Exelixis-Partnered XB404 SAFEbody ADC, Triggers $2 Million Payment

Reuters
·
Sep 09

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

GlobeNewswire
·
Sep 09